



# Youth-Onset Type 2 Diabetes: How to Identify, Screen, and Treat

## Contributing authors on behalf of Team Best Practices:

**Anuradha Viswanathan, MD**

Case Western Reserve University

**Ryan Farrell, MD**

Case Western Reserve University

**Rose Gubitosi-Klug, MD, PhD**

Case Western Reserve University

The recognition of youth-onset type 2 diabetes (T2D) parallels the rise in obesity among children.<sup>1,2</sup>

Youth-onset T2D has distinct features from both type 1 diabetes in youth and type 2 diabetes in adults (Table 1).<sup>3,4</sup> Identifying those children at highest risk for T2D may allow for better screening and earlier diagnosis and treatment.

This document highlights distinguishing characteristics of youth-onset type 2 diabetes and identifies the most vulnerable patients that need screened. Also included is a review of treatment options, how to identify those patients at highest risk of requiring insulin, and discussion of the rapid development of complications in this population.



**Youth-onset T2D leads to more rapid development of diabetes complications and requires early recognition and aggressive treatment from the time of diagnosis.**

TABLE 1

## Features of Type 1 Diabetes Compared to Youth-Onset Type 2 Diabetes

Features	Type 1 Diabetes	Youth-Onset Type 2 Diabetes
<b>Race/Ethnicity</b>	More common in Caucasians	80% of youth-onset T2D are racial and ethnic minorities
<b>Sex</b>	Equally common in females and males	More common in females
<b>Body Habitus</b>	Normal/underweight; no features of insulin resistance	Overweight or obese, features suggestive of insulin resistance such as acanthosis nigricans
<b>Screening:</b> (Symptoms: polyuria, polydipsia, nocturia, weight loss)	Symptomatic	Symptomatic, or at time of puberty or age 10 years, whichever is sooner, for at-risk racial and ethnic minorities
<b>Diagnostic Testing</b>	American Diabetes Association criteria: Fasting glucose (>126 mg/dL), or two-hour glucose during an oral glucose tolerance test (>200 mg/dL), or HbA1C (≥6.5%)	American Diabetes Association criteria, or presence of symptoms and random glucose >200mg/dL HbA1C of 6.5% may not identify all youth with early T2D
<b>Symptom-onset</b>	Rapid onset of symptoms; often present in ketoacidosis	Gradual onset of symptoms; occasional ketoacidosis
<b>Pathophysiology:</b> Autoimmunity	Autoimmunity present	Autoimmunity absent; should exclude type 1 diabetes with antibody testing
Pancreatic function	Insulin deficiency	Insulin resistance due to puberty as well as increased adiposity and stress; decreased exercise and sleep; and rapid beta cell failure
<b>Family History</b>	Family association with other autoimmune disorders, but may be only individual with type 1 diabetes in family	Strong family history of type 2 diabetes; in utero exposure to maternal gestational diabetes mellitus
<b>Treatment Options</b>	Managed with insulin	Lifestyle plus pharmacotherapy; rapidly progress to requiring insulin (>50% by 2-5 years after diagnosis) <sup>1</sup>

### Screening for Youth-Onset Type 2 Diabetes<sup>4</sup>

Identifying youth with type 2 diabetes and starting treatment early is critical to prevent complications. Consider screening with symptoms or high risk features as described below:

- Symptomatic individuals with polyuria, polydipsia, nocturia, or enuresis should be screened.
- Overweight or obese individuals at the time of puberty or >10 years of age with one or more additional risk factor:
  - Racial and ethnic minorities (Native American, African American, Latino/Latina, Asian American, Pacific Islander)
  - T2D in first- or second-degree relative
  - Maternal history of gestational diabetes
  - Physical exam or lab findings associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, small-for-gestational-age birth weight)

## The Importance of Treatment

Several clinical trials of youth-onset T2D uncover an aggressive decline in beta cell function and early treatment failure of oral medications, which correlate with elevated glucose levels and rapid progression to complications including diabetic retinopathy, diabetic kidney disease, diabetic peripheral neuropathy, cardiovascular disease and stroke while only in their mid-20s.<sup>3</sup> When treating youth-onset T2D, consider screening for obstructive sleep apnea, depression and anxiety, eating disorders, cognitive delays, and polycystic ovary syndrome.

Treatment begins at the time of diagnosis with lifestyle, psychosocial, and pharmacologic interventions.

### Lifestyle Changes:

Diet and physical activity can play a role in treating T2D:

- Diet modifications include avoiding sugar sweetened beverages, limiting portion sizes, minimizing processed carbohydrates, and increasing vegetable and fruit servings.<sup>5</sup>
- Cardiovascular exercise should include 60 minutes of activity daily, with half at moderate to vigorous levels.<sup>4</sup>
  - One-fourth of females and one-third of males are successful in achieving better cardiovascular fitness, which is associated with better glycemic control.<sup>5</sup>

### Psychosocial and Social Determinants of Health Assessment:

High rates of depression (~15%) and disordered eating (25% for both males and females); lower socioeconomic status, higher unemployment, food insecurity, and housing instability all negatively impact glycemic control.<sup>4</sup> Perform the following to assess psychosocial factors:

- Assess social barriers at each visit, and integrate social workers into care early as indicated.
- Screen for diabetes distress and assess mental health frequently, and make a psychology/psychiatry referral as appropriate.
- Discuss preconception counseling given that 10% of females became pregnant over an average of 3.8 years in longitudinal studies.

### Metformin:

This is a first line treatment due to cost, safety, and efficacy, indicated for children with newly diagnosed T2D based on American Diabetes Association (ADA) criteria, along with lifestyle changes. However, it does have limitations and is important to consider the following:

- High treatment failure rates (almost half within three years of starting treatment) are likely due to increased insulin resistance of puberty.
- Lactic acidosis is incredibly rare in children. Hold in the situation of vomiting or IV contrast.
- Half of patients treated experience significant gastrointestinal adverse effects. Titrate the dose as tolerated (start with 500 mg daily and increase by 500 mg per day weekly until at 2,000 mg per day or maximum tolerated dose).
- HbA1C >6.3% shortly after starting metformin predicts higher rates of treatment failure in youth on metformin monotherapy.<sup>6</sup> Rises in A1C beyond 6.5-7% may indicate the need for treatment escalation.

## Liraglutide:

In 2019, the U.S. Food and Drug Administration (FDA) approved this for youth with T2D (ages 10 and up).<sup>7</sup> It may serve as next-line therapy, demonstrating a mean HbA1C reduction of 0.64%. Nearly two-thirds of patients achieve HbA1C <7%.

Additional benefits and drawbacks include:

- May preserve insulin production
- May help with weight loss
- Higher cost
- Injection may negatively affect adherence

## Insulin:

Use as a rescue treatment if HbA1C rises to >8-9% or fasting glucose is >200-250 mg/dL.

- May be able to start with basal insulin only (0.25-0.5 u/kg), but may require mealtime insulin if there is decompensation.
- Youth presenting with decompensation/diabetic ketoacidosis may require insulin initially, with the chance to wean off it rapidly once the condition is stabilized and metformin is initiated.

**Other medications (sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors) are not FDA approved for youth-onset T2D.**

## Patient Monitoring: Frequency and Referral

Youth with type 2 diabetes require frequent clinic follow-up and recommended monitoring for co-morbidities and complications.

	At Diagnosis	Quarterly	Annually
<b>HbA1C</b> (with target less than 7%)		X	
<b>Blood Pressure</b>		X	
<b>Liver Function Test</b>			X
<b>Lipid Profile</b>			X
<b>Urine Albumin</b>			X
<b>Glomerular Filtration Rate</b> (hyperfiltration followed by rapidly declining filtration)			X
<b>Eye Exam</b>	X		X
<b>Foot Exam</b>			X
<b>Psych Comorbidities</b>	X	X	X
<b>Social Determinants of Health</b>	X	X	X

If the patient is unable to reach target HbA1C <7% within the first six months of care, referral to an endocrinologist is appropriate. Care may require additional support by a multi-disciplinary team that includes a certified diabetes care and education specialist, psychologist, dietitian, and social worker.


## Also Consider and Exclude MODY

### Monogenic Diabetes

Monogenic Diabetes requires genetic testing to confirm the diagnosis based on clinical suspicion. Treatment and surveillance of MODY is specific to MODY type and referral to a pediatric endocrinologist is recommended.

MODY has the following features:

- Heterogeneous group of disorders
- Autosomal dominant inheritance (e.g., two and preferably three consecutive affected generations)
- More prevalent in Caucasians
- Mostly normal Body Mass Index – rising obesity rates may obscure the suspicion
- Usually diagnosed under 25 years old
- 2-5% of individuals with youth-onset diabetes may have MODY
- 65% of MODY cases are MODY 3
- MODY 5 is associated with renal cysts or other renopelvic anomalies
- MODY 2 may present with stable mild hyperglycemia that may not require aggressive treatment



Prevalence of youth-onset T2D is rising in the population, especially in ethnic minorities. Early and aggressive management is indicated as youth-onset T2D leads to early development and rapid progression of complications. Management includes lifestyle changes, mitigating psychosocial factors and pharmacologic interventions. At present Metformin, Liraglutide, and Insulin are the three U.S. Food and Drug Administration approved pharmacologic interventions.

## References:

1. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*. 2012;366(24):2247-2256. doi:10.1056/NEJMoa1109333.
2. Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. *Diabetes Care*. 2014;37(12):3336-3344. doi:10.2337/dc14-0574.
3. RISE Consortium. Impact of insulin and metformin versus metformin alone on  $\beta$ -cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. *Diabetes Care*. 2018;41(8):1717-1725. doi:10.2337/dc18-0787.
4. Arslanian S, Bacha F, Grey M, et al. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. *Diabetes Care*. 2018;41(12):2648-2668. doi:10.2337/dci18-0052.
5. TODAY Study Group, Kriska A, El Ghormli L, et al. Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. *Pediatr Diabetes*. 2018;19(1): 36-44. doi:10.1111/pedi.12526.
6. Zeitler P, Hirst K, Copeland KC, et al. HbA1C after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. *Diabetes Care*. 2015;38(12):2285-2292. doi:10.2337/dc15-0848.
7. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. *N Engl J Med*. 2019;381(7):637-646. doi:10.1056/NEJMoa1903822.

---

## Partners



In partnership with:



---

The Ohio Cardiovascular & Diabetes Health Collaborative is funded by the Ohio Department of Medicaid and administered by the Ohio Colleges of Medicine Government Resource Center. The views expressed in this document are solely those of the authors and do not represent the views of the state of Ohio or federal Medicaid programs.